Compare YDKG & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YDKG | BIAF |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | China | United States |
| Employees | N/A | 57 |
| Industry | Advertising | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 4.6M |
| IPO Year | N/A | N/A |
| Metric | YDKG | BIAF |
|---|---|---|
| Price | $0.82 | $1.05 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 67.1K | ★ 476.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $0.16 |
| 52 Week High | $3.90 | $13.50 |
| Indicator | YDKG | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 43.34 | 47.73 |
| Support Level | $0.81 | $0.92 |
| Resistance Level | $1.04 | $1.45 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 10.21 | 32.61 |
Yueda Digital Holding is a digital-economy company with a focus on the long-term accumulation of mainstream cryptocurrencies. The business activities of the company include active treasury management of mainstream digital assets, exploration of compliant, risk-managed yield opportunities, such as staking, on-chain liquidity provision, and other conservative market activities, selective investments and partnerships in Web3 infrastructure and applications, and advisory services for enterprises entering the digital-asset economy.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.